In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog NNZ-2591 | Natural fragment Davunetide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural fragment | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 23 | 297 | |
| Evidence level | Results from animal studies onlyRegistered trials, no results from human studies | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 8 (7 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | 7 · 2 active | 5 | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | NNZ-2591 | Davunetide |
|---|---|---|
| NeuroprotectionNervous system and cognition | 88 | 11966548 |
| Receptor activity and mechanism |
PepBank is a research reference. Talk to a doctor before you use any peptide.
66 |
893158 |
| Cognition and memoryNervous system and cognition | 22 | 371423 |
|---|
| Exercise and physical functionNervous system and cognition | 33 | 1569 |
|---|
| PharmacokineticsPharmacology | 33 | 6213 |
|---|
| Inflammation markersNervous system and cognition | 11 | 413 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | NNZ-2591 | Davunetide |
|---|---|---|
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in na | No randomized trial result 3 results from other study designs. | 11.8 NA PSPRS median change from baseline Placebo: 11.8 NA Dose studied: 30 mg twice daily52 weeksn = 3132014 |
No randomized trial result
3 results from other study designs.
11.8 NA
PSPRS median change from baseline
Placebo: 11.8 NA
Dose studied: 30 mg twice daily52 weeksn = 3132014
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 7 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Neuren Pharmaceuticals Limited180 participants8 Jun 2026 to est. 12 Nov 2028
Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited160 participants12 Nov 2025 to est. 15 Nov 2027
Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited28 participants14 Oct 2022 to 3 May 2024
Pitt Hopkins Syndrome
Top 3 of 5 trials, ranked by phase, then posted results and enrollment: 3 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Allon Therapeutics313 participantsOct 2010 to Dec 2012
Progressive Supranuclear Palsy
University of California, Los Angeles63 participantsJul 2007 to Apr 2009
Schizophrenia
Allon Therapeutics234 participantsAug 2006 to Jun 2008
Mild Cognitive Impairment